Chromogranin  ||| S:0 E:13 ||| NNP
A  ||| S:13 E:15 ||| NNP
( ||| S:15 E:16 ||| -LRB-
CgA ||| S:16 E:19 ||| NNP
)  ||| S:19 E:21 ||| -RRB-
-  ||| S:21 E:23 ||| :
the  ||| S:23 E:27 ||| DT
influence  ||| S:27 E:37 ||| NN
of  ||| S:37 E:40 ||| IN
various  ||| S:40 E:48 ||| JJ
factors  ||| S:48 E:56 ||| NNS
in  ||| S:56 E:59 ||| IN
vivo  ||| S:59 E:64 ||| NN
and  ||| S:64 E:68 ||| CC
in  ||| S:68 E:71 ||| IN
vitro ||| S:71 E:76 ||| NN
,  ||| S:76 E:78 ||| ,
and  ||| S:78 E:82 ||| CC
existing  ||| S:82 E:91 ||| VBG
disorders  ||| S:91 E:101 ||| NNS
on  ||| S:101 E:104 ||| IN
it ||| S:104 E:106 ||| PRP
's  ||| S:106 E:109 ||| VBZ
concentration  ||| S:109 E:123 ||| VBN
in  ||| S:123 E:126 ||| IN
blood  ||| S:126 E:132 ||| NN
Chromogranin  ||| S:132 E:145 ||| NNP
A  ||| S:145 E:147 ||| NNP
( ||| S:147 E:148 ||| -LRB-
CgA ||| S:148 E:151 ||| NNP
)  ||| S:151 E:153 ||| -RRB-
is  ||| S:153 E:156 ||| VBZ
regarded  ||| S:156 E:165 ||| VBN
as  ||| S:165 E:168 ||| IN
a  ||| S:168 E:170 ||| DT
major ||| S:170 E:175 ||| JJ
,  ||| S:175 E:177 ||| ,
nonspecific  ||| S:177 E:189 ||| FW
neuroendocrine  ||| S:189 E:204 ||| FW
tumour  ||| S:204 E:211 ||| FW
( ||| S:211 E:212 ||| -LRB-
NET ||| S:212 E:215 ||| NNP
)  ||| S:215 E:217 ||| -RRB-
marker ||| S:217 E:223 ||| NN
.  ||| S:223 E:225 ||| .
The  ||| S:225 E:229 ||| DT
results  ||| S:229 E:237 ||| NNS
of  ||| S:237 E:240 ||| IN
CgA  ||| S:240 E:244 ||| JJ
blood  ||| S:244 E:250 ||| NN
concentration ||| S:250 E:263 ||| NN
,  ||| S:263 E:265 ||| ,
however ||| S:265 E:272 ||| RB
,  ||| S:272 E:274 ||| ,
may  ||| S:274 E:278 ||| MD
actually  ||| S:278 E:287 ||| RB
be  ||| S:287 E:290 ||| VB
influenced  ||| S:290 E:301 ||| VBN
by  ||| S:301 E:304 ||| IN
various  ||| S:304 E:312 ||| JJ
factors  ||| S:312 E:320 ||| NNS
or  ||| S:320 E:323 ||| CC
coexisting  ||| S:323 E:334 ||| JJ
pathological  ||| S:334 E:347 ||| JJ
conditions ||| S:347 E:357 ||| NNS
.  ||| S:357 E:359 ||| .
Among  ||| S:359 E:365 ||| IN
the  ||| S:365 E:369 ||| DT
factors  ||| S:369 E:377 ||| NNS
causing  ||| S:377 E:385 ||| VBG
a  ||| S:385 E:387 ||| DT
substantial  ||| S:387 E:399 ||| JJ
increase  ||| S:399 E:408 ||| NN
of  ||| S:408 E:411 ||| IN
the  ||| S:411 E:415 ||| DT
blood  ||| S:415 E:421 ||| NN
CgA  ||| S:421 E:425 ||| JJ
concentration  ||| S:425 E:439 ||| NNS
are ||| S:439 E:442 ||| VBP
:  ||| S:442 E:444 ||| :
treatment  ||| S:444 E:454 ||| NN
with  ||| S:454 E:459 ||| IN
proton-pump  ||| S:459 E:471 ||| JJ
inhibitors  ||| S:471 E:482 ||| NN
or  ||| S:482 E:485 ||| CC
H2  ||| S:485 E:488 ||| CD
-receptor  ||| S:488 E:498 ||| JJ
blockers ||| S:498 E:506 ||| NN
,  ||| S:506 E:508 ||| ,
chronic  ||| S:508 E:516 ||| FW
atrophic  ||| S:516 E:525 ||| FW
gastritis  ||| S:525 E:535 ||| FW
( ||| S:535 E:536 ||| -LRB-
type  ||| S:536 E:541 ||| NN
A ||| S:541 E:542 ||| NNP
) ||| S:542 E:543 ||| -RRB-
,  ||| S:543 E:545 ||| ,
impaired  ||| S:545 E:554 ||| VBN
renal  ||| S:554 E:560 ||| JJ
function ||| S:560 E:568 ||| NN
,  ||| S:568 E:570 ||| ,
prostate  ||| S:570 E:579 ||| JJ
cancer  ||| S:579 E:586 ||| NN
and  ||| S:586 E:590 ||| CC
BPH ||| S:590 E:593 ||| NNP
,  ||| S:593 E:595 ||| ,
and  ||| S:595 E:599 ||| CC
rheumatoid  ||| S:599 E:610 ||| JJ
arthritis  ||| S:610 E:620 ||| NN
with  ||| S:620 E:625 ||| IN
high  ||| S:625 E:630 ||| JJ
level  ||| S:630 E:636 ||| NN
of  ||| S:636 E:639 ||| IN
RF  ||| S:639 E:642 ||| NNP
IgM ||| S:642 E:645 ||| NNP
.  ||| S:645 E:647 ||| .
In  ||| S:647 E:650 ||| IN
addition ||| S:650 E:658 ||| NN
,  ||| S:658 E:660 ||| ,
the  ||| S:660 E:664 ||| DT
sort  ||| S:664 E:669 ||| NN
of  ||| S:669 E:672 ||| IN
investigated  ||| S:672 E:685 ||| JJ
biological  ||| S:685 E:696 ||| JJ
material  ||| S:696 E:705 ||| NN
( ||| S:705 E:706 ||| -LRB-
whether  ||| S:706 E:714 ||| IN
it  ||| S:714 E:717 ||| PRP
is  ||| S:717 E:720 ||| VBZ
serum  ||| S:720 E:726 ||| VBN
or  ||| S:726 E:729 ||| CC
plasma ||| S:729 E:735 ||| CD
)  ||| S:735 E:737 ||| -RRB-
is  ||| S:737 E:740 ||| VBZ
of  ||| S:740 E:743 ||| IN
importance ||| S:743 E:753 ||| NN
.  ||| S:753 E:755 ||| .
There  ||| S:755 E:761 ||| EX
are  ||| S:761 E:765 ||| VBP
also  ||| S:765 E:770 ||| RB
many  ||| S:770 E:775 ||| JJ
conditions  ||| S:775 E:786 ||| NNS
which  ||| S:786 E:792 ||| WDT
may  ||| S:792 E:796 ||| MD
have  ||| S:796 E:801 ||| VB
a  ||| S:801 E:803 ||| DT
moderate  ||| S:803 E:812 ||| JJ
or  ||| S:812 E:815 ||| CC
little  ||| S:815 E:822 ||| JJ
influence  ||| S:822 E:832 ||| NN
on  ||| S:832 E:835 ||| IN
the  ||| S:835 E:839 ||| DT
concentration  ||| S:839 E:853 ||| NN
of  ||| S:853 E:856 ||| IN
CgA ||| S:856 E:859 ||| NNP
,  ||| S:859 E:861 ||| ,
among  ||| S:861 E:867 ||| IN
them  ||| S:867 E:872 ||| PRP
are ||| S:872 E:875 ||| VBP
:  ||| S:875 E:877 ||| :
inflammatory  ||| S:877 E:890 ||| JJ
bowel  ||| S:890 E:896 ||| JJ
disease  ||| S:896 E:904 ||| NN
( ||| S:904 E:905 ||| -LRB-
ulcerative  ||| S:905 E:916 ||| JJ
colitis  ||| S:916 E:924 ||| NN
and  ||| S:924 E:928 ||| CC
Crohn ||| S:928 E:933 ||| NNP
's  ||| S:933 E:936 ||| POS
disease ||| S:936 E:943 ||| NN
) ||| S:943 E:944 ||| -RRB-
,  ||| S:944 E:946 ||| ,
deteriorating  ||| S:946 E:960 ||| VBG
liver  ||| S:960 E:966 ||| JJ
function ||| S:966 E:974 ||| NN
,  ||| S:974 E:976 ||| ,
untreated  ||| S:976 E:986 ||| JJ
essential  ||| S:986 E:996 ||| JJ
hypertension ||| S:996 E:1008 ||| NN
,  ||| S:1008 E:1010 ||| ,
heart  ||| S:1010 E:1016 ||| NN
failure ||| S:1016 E:1023 ||| NN
,  ||| S:1023 E:1025 ||| ,
hypercortisolism ||| S:1025 E:1041 ||| NN
,  ||| S:1041 E:1043 ||| ,
pregnancy ||| S:1043 E:1052 ||| NN
,  ||| S:1052 E:1054 ||| ,
and ||| S:1054 E:1057 ||| CC
,  ||| S:1057 E:1059 ||| ,
in  ||| S:1059 E:1062 ||| IN
some  ||| S:1062 E:1067 ||| DT
subjects ||| S:1067 E:1075 ||| NNS
,  ||| S:1075 E:1077 ||| ,
ingestion  ||| S:1077 E:1087 ||| NN
of  ||| S:1087 E:1090 ||| IN
a  ||| S:1090 E:1092 ||| DT
meal ||| S:1092 E:1096 ||| NN
.  ||| S:1096 E:1098 ||| .
Proper  ||| S:1098 E:1105 ||| JJ
assessment  ||| S:1105 E:1116 ||| NN
of  ||| S:1116 E:1119 ||| IN
the  ||| S:1119 E:1123 ||| DT
CgA  ||| S:1123 E:1127 ||| JJ
results  ||| S:1127 E:1135 ||| NNS
requires  ||| S:1135 E:1144 ||| VBZ
detailed  ||| S:1144 E:1153 ||| JJ
knowledge  ||| S:1153 E:1163 ||| NN
about  ||| S:1163 E:1169 ||| IN
various  ||| S:1169 E:1177 ||| JJ
factors ||| S:1177 E:1184 ||| NNS
,  ||| S:1184 E:1186 ||| ,
drugs ||| S:1186 E:1191 ||| NNS
,  ||| S:1191 E:1193 ||| ,
and  ||| S:1193 E:1197 ||| CC
pathological  ||| S:1197 E:1210 ||| JJ
conditions  ||| S:1210 E:1221 ||| NNS
influencing  ||| S:1221 E:1233 ||| VBG
its  ||| S:1233 E:1237 ||| PRP$
concentration  ||| S:1237 E:1251 ||| NN
in  ||| S:1251 E:1254 ||| IN
blood ||| S:1254 E:1259 ||| NN
.  ||| S:1259 E:1261 ||| .
